OpGen (OPGN) Downgraded to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of OpGen (NASDAQ:OPGN) from a buy rating to a hold rating in a research report report published on Friday.

According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “

Other analysts have also issued reports about the stock. HC Wainwright restated a buy rating and issued a $25.00 price objective on shares of OpGen in a report on Tuesday, October 24th. ValuEngine lowered shares of OpGen from a sell rating to a strong sell rating in a report on Thursday, January 25th.

OpGen (NASDAQ OPGN) traded up $0.17 during midday trading on Friday, hitting $2.03. The company had a trading volume of 410,094 shares, compared to its average volume of 787,880. The company has a quick ratio of 1.13, a current ratio of 1.23 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $9.15, a PE ratio of -0.13 and a beta of 0.71. OpGen has a 12 month low of $1.85 and a 12 month high of $31.25.

A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. boosted its stake in OpGen Inc (NASDAQ:OPGN) by 1.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 342,860 shares of the medical research company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned 1.25% of OpGen worth $219,000 at the end of the most recent reporting period.

TRADEMARK VIOLATION NOTICE: “OpGen (OPGN) Downgraded to “Hold” at Zacks Investment Research” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/17/opgen-opgn-downgraded-to-hold-at-zacks-investment-research-2.html.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply